Genetic polymorphism of paraoxonase and the risk of coronary heart disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 6, 1997, Pages 1067-1073

  Sanghera, Dharambir K ^a   Saha, Nilmani ^a   Aston, Christopher E ^a   Ilyas Kamboh, M ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Asian Indians; Chinese; Coronary heart disease; Genetic polymorphism; High density lipoprotein; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; CHINESE; CONTROLLED STUDY; CORONARY RISK; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030987447     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.6.1067     Document Type: Article

References (43)

1. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation. 1992;86(suppl III): III-86-III-94.
2. Tribble DL, Kraus RM. HDL and coronary artery disease. Adv Intern Med. 1993:38:1-29.
3. Parthasarathy S, Harriett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biopliys Ada. 1990;1044:275-283.
4. Klimov AN, Gurevich VS, Nikiforova AA, Shatiiina LV, Kuzmin AA, Plavinsky SL, Teryukova NP. Antioxidative activity of high density lipoprotein in vivo. Atherosclerosis. 1993;100:13-18.
5. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-253.
6. Mackness MI. The human serum paraoxonase polymorphism and atherosclerosis. In: Mackness MI, Clerc M, eds. Esterase, Upases and Pliospholipases. New York, NY: Plenum Press; 1994:65-73.
7. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of high density lipoprotein subspecies defined by a lipoproteinassociated protein, k-45. Ear J Biochcm. 1993;211:871-879.
8. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony AK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994:33:832-839.
9. Diepgen TL, Geldmacher-von Mallinckrodt M. Intercthnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. Arch Toxicol. 1986;9(suppl):154-158.
10. Roy AC, Saha N, Tay JSH, Ratnam SS. Serum paraoxonase polymorphism in three populations of Southeast Asia. Hum Hered. 1991;141:265-269.
11. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
12. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furling CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991;30:10141-10149.
13. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
14. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxonase hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986:32:671-673.
15. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991:86:193-199.
16. Mackness MI, Walker CH, Carlson LA. Low 'A'-esterase activity in serum of patients with fish-eye disease. Clin Chem. 1987;33: 587-588.
17. Mackness MI, Peuchant E, Dumon M-F, Walker CH, Clerc M. Absence of 'A'-esterase activity in serum of patients with Tangier disease. Clin Biochem. 1989;22:475-478.
18. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med. 1981;25:373-378.
19. Abbott CA, Mackness MI, Kumar S, Boulton A, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arlerioscler Thromb Vase Biol. 1995:15:1812-1818.
20. Saha N, Rpy AC, Teo SH, Tay JSH, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 1991;40:277-282.
21. Ruiz J, Blanche H, James RW, Garin M-CB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995:346:869-872.
22. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96:3005-3008.
23. Hughes K, Lun KC, Yeo PPB. Cardiovascular disease in Chinese, Malays and Indians in Singapore, I: differences in mortality. J Epidemiol Commun Health. 1990:44:24-28.
24. Hughes K, Yeo PPB, Lun KC, Thai AC, Sothy SP, Wang KW, Cheah JS, Phoon WO, Lim P., Cardiovascular disease in Chinese, Malays and Indians in Singapore, II: differences in risk factor levels. J Epidemiol Commun Health. 1990:44:29-35.
25. Saha N. Serum high density lipoprotein cholesterol, apolipoprotein A-I, A-II, and B levels in Singapore ethnic groups. Atherosclerosis. 1987:68:117-121.
26. Saha N, Tay JSH, Low PS, Humphries SE. Guanidine to adenine (G/A) substitution in the promotor region of the apolipoprotein A-I gene associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol. 1994;11:255-264.
27. Friedewald WT, Levi RI, Fredrickson DS. Estimation of low density lipoprotein cholesterol levels in plasma without use of the preparative ultracentrifuge. Clin Client. 1972;18:499-502.
28. Parzer S, Mannhalter CA. Rapid method for the isolation of genomic DNA from citrate whole blood. Biocitem J. 1991;273:229-231.
29. Kanji GK. 700 Statistical Tests. Newbury Park, Calif: Sage Publications; 1993.
30. Boerwinkle E, Sing CF. Bias of the contribution of single locus effects to the variance of a quantitative trait. Am J Hum Genet. 1986;39:137-144.
31. McCullagh P, Neider JA. Generalized Linear Models. New York, NY: Chapman & Hall; 1983.
32. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Tliromb Vase Biol. 1995;15:89-95.
33. Roychoudhury AK. Genetic polymorphisms in human populations of India. In: People of India: Some Genetical Aspects. New Delhi, India: Indian Council of Medical Research; 1983:1-30.
34. Primo-Parmo SL, Sorenson RC, Teiber J, La Du N. The human serum paraoxonase/arylesterase gene (PON1) is one member of multigene family. Genomics. 1996;33:498-507.
35. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, Mcintyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.
36. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherosclerosis in a mouse model. J Clin luvest. 1996;97:1630-1639.
37. Saha N, Tan PY, Sothy SP, Ng TB, Lim CH. Traditional dietary intakes and serum lipids in Singapore ethnic groups. Proc Nutr Soc. 1992;52:14A. Abstract.
38. Tan PY, Ng TB, Saha N. Dietary intakes of three ethnic groups in Singapore. Proc Nutr Soc. 1984;43:135A. Abstract.
39. Blatter-Garin M, Abbot CA, Messmer S, Mackness MI, Durrington PN, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. BiochemJ. 1994;304:549-554.
40. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of LDL low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
41. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991 ;88:1785-1792.
42. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
43. Van Lanten BJ, Hama SY, deBaer FC, Stafforini DM, Mcintyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767.